This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chen, Q. Articles by Anderson, G. M. Search for Related Content PubMed PubMed Citation Articles by Chen, Q. Articles by Anderson, G. M.

_v Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models

Authors' Affiliations: ¹ Oncology Research, Centocor R&D, Inc., Malvern, Pennsylvania and ² ImmunoGen, Inc., Cambridge, Massachusetts

Requests for reprints: Qiming Chen, Oncology Research, Centocor R&D, Inc., 145 King of Prussia Road, Radnor, PA 19087. Phone: 610-240-8015; Fax: 610-889-4418; E-mail: qchen2{at}cntus.jnj.com.

Purpose: Targeted delivery of cytotoxic agents to solid tumors through cell surface antigens can potentially reduce systemic toxicity and increase the efficacy of the targeted compounds. The purpose of this study was to show the feasibility of treating solid tumors by targeting _v integrins with antibody-maytansinoid conjugates and to test the relative in vivo activities of several linker-maytansinoid chemistries.

Experimental Design: CNTO 364, CNTO 365, and CNTO 366 are targeted cytotoxic agents created by conjugating the CNTO 95 anti-_v integrin antibody with three distinct maytansinoid-linker structures. These structures were designed to have varying degrees of chemical substitution surrounding the disulfide bond linking the cytotoxic agent to the antibody. A model conjugate was shown to be specifically cytotoxic in vitro and highly active against established human tumor xenografts in immunocompromised rats. The in vivo antitumor activities of CNTO 364, CNTO 365, and CNTO 366 were compared in rat xenograft models.

Results: CNTO 365, with a linker chemistry of expected intermediate stability, was shown to be substantially more active than the other two conjugates with lesser or greater substitution around the disulfide linkage.

Conclusion: CNTO 95–maytansinoid immunoconjugates are potent antitumor agents against _v integrin–expressing human carcinomas. These studies show for the first time the feasibility of targeting _v integrins on solid tumors with tumor-activated prodrugs. The DM4 linker-maytansinoid configuration of CNTO 365 was substantially more active in the models tested here when compared with alternative configurations with greater or lesser chemical substitution surrounding the linker.